Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial
- 435 Downloads
Gestational diabetes mellitus (GDM) is a condition that affects increasing number of pregnant women worldwide. Sitagliptin was reported to alleviate symptoms of type 2 diabetes mellitus by reducing serum levels of retinol-binding protein 4 (RBP-4). We investigated the effectiveness of sitagliptin on insulin sensitivity parameters in GDM patients. Pregnant GDM women in the 2nd trimester were recruited for this study. Participants were then assigned randomly to sitagliptin treatment group or placebo treatment group, and administered sitagliptin or placebo daily for 16 weeks. Glucose and insulin profiles, as well as serum RBP-4 level, were measured at both baseline and end of the study. After 16 weeks of treatment, participants in the STL group exhibited significantly improved levels of fasting plasma glucose and serum insulin, homeostasis model of assessment of β cell function (HOMA-β) and insulin resistance (HOMA-IR), compared with those in the placebo group. Serum levels of RBP-4 were also markedly decreased in the sitagliptin treatment group, and more importantly it was positively correlated with improved insulin resistance parameters. Our study supports a potentially promising role of sitagliptin in improving insulin resistance by decreasing RBP-4 in GDM-affected women.
KeywordsSitagliptin Gestational diabetes mellitus Insulin resistance Dipeptidyl peptidase-4 Retinol-binding protein 4
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P (2012) A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin Pharmacother 13:2433–2442. doi: 10.1517/14656566.2012.730519 CrossRefPubMedGoogle Scholar
- Hamza N, Berke B, Cheze C, Agli AN, Robinson P, Gin H, Moore N (2010) Prevention of type 2 diabetes induced by high fat diet in the C57BL/6 J mouse by two medicinal plants used in traditional treatment of diabetes in the east of Algeria. J Ethnopharmacol 128:513–518. doi: 10.1016/j.jep.2010.01.004 CrossRefPubMedGoogle Scholar
- Kondo Y et al (2016) Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Diabetol Metab Syndr 8:15. doi: 10.1186/s13098-016-0131-y CrossRefPubMedPubMedCentralGoogle Scholar
- Legardeur H, Girard G, Journy N, Ressencourt V, Durand-Zaleski I, Mandelbrot L (2014) Factors predictive of macrosomia in pregnancies with a positive oral glucose challenge test: importance of fasting plasma glucose. Diabetes Metab 40:43–48. doi: 10.1016/j.diabet.2013.01.008 CrossRefPubMedGoogle Scholar